|
1
|
Zeferino LC and Derchain SF: Cervical
cancer in the developing world. Best Pract Res Clin Obstet
Gynaecol. 20:339–354. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ohazurike E, Anorlu I, Okunade K, Okunowo
A and Sajo A: Cervical cancer: An urgent need to scale up screening
in the developing world. Int J Gynecol Cancer. 27:842. 2017.
|
|
3
|
Nogueira-Rodrigues A, de Melo AC, Garces
AHI, Paulino E, Alves FV, Vilaça Mdo N, Silva LG, Gonçalves CA,
Fabrini JC, Carneiro AT and Thuler LC: Patterns of care and outcome
of elderly women diagnosed with cervical cancer in the developing
world. Int J Gynecol Cancer. 26:1246–1251. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rao GG, Rogers P, Drake RD, Nguyen P and
Coleman RL: Phase I clinical trial of weekly paclitaxel, weekly
carboplatin, and concurrent radiotherapy for primary cervical
cancer. Gynecol Oncol. 96:168–172. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Falcetta FS, Medeiros LR, Edelweiss MI,
Pohlmann PR, Stein AT and Rosa DD: Adjuvant platinum-based
chemotherapy for early stage cervical cancer. Cochrane Database
Syst Rev. 11:CD0053422016.PubMed/NCBI
|
|
6
|
Rosa DD, Medeiros LR, Edelweiss MI,
Bozzetti MC, Pohlmann PR, Stein AT and Dickinson HO: Adjuvant
platinum-based chemotherapy for early stage cervical cancer.
Cochrane Database Syst Rev. CD0053422009.PubMed/NCBI
|
|
7
|
Rosa DD, Medeiros LR, Edelweiss MI,
Pohlmann PR and Stein AT: Adjuvant platinum-based chemotherapy for
early stage cervical cancer. Cochrane Database Syst Rev.
CD0053422012.PubMed/NCBI
|
|
8
|
Kung JT, Colognori D and Lee JT: Long
noncoding RNAs: Past, present, and future. Genetics. 193:651–669.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jin XJ, Chen XJ, Hu Y, Ying F, Zou R, Lin
F, Shi Z, Zhu X, Yan X, Li S and Zhu H: LncRNA-TCONS_00026907 is
involved in the progression and prognosis of cervical cancer
through inhibiting miR-143-5p. Cancer Med. 6:1409–1423. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang J, Yao T, Wang Y, Yu J, Liu Y and
Lin Z: Long noncoding RNA MEG3 is downregulated in cervical cancer
and affects cell proliferation and apoptosis by regulating miR-21.
Cancer Biol Ther. 17:104–113. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jiang Y, Li Y, Fang S, Jiang B, Qin C, Xie
P, Zhou G and Li G: The role of MALAT1 correlates with HPV in
cervical cancer. Oncol Lett. 7:2135–2141. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Di Sanzo M, Aversa I, Santamaria G,
Gagliardi M, Panebianco M, Biamonte F, Zolea F, Faniello MC, Cuda G
and Costanzo F: FTH1P3, a Novel H-Ferritin pseudogene
transcriptionally active, is ubiquitously expressed and regulated
during cell differentiation. PLoS One. 11:e01513592016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang CZ: Long non-coding RNA FTH1P3
facilitates oral squamous cell carcinoma progression by acting as a
molecular sponge of miR-224-5p to modulate fizzled 5 expression.
Gene. 607:47–55. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zovoilis A, Mungall AJ, Moore R, Varhol R,
Chu A, Wong T, Marra M and Jones SJ: The expression level of small
non-coding RNAs derived from the first exon of protein-coding genes
is predictive of cancer status. EMBO Rep. 15:402–410. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chaudhry MA: Expression pattern of small
nucleolar RNA host genes and long non-coding RNA in X-rays-treated
lymphoblastoid cells. Int J Mol Sci. 14:9099–9110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Aalto AP and Pasquinelli AE: Small
non-coding RNAs mount a silent revolution in gene expression. Curr
Opin Cell Biol. 24:333–340. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Braconi C, Henry JC, Kogure T, Schmittgen
T and Patel T: The role of MicroRNAs in human liver cancers. Semin
Oncol. 38:752–763. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wilmott JS, Zhang XD, Hersey P and Scolyer
RA: The emerging important role of microRNAs in the pathogenesis,
diagnosis and treatment of human cancers. Pathology. 43:657–671.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Esquela-Kerscher A: From worms to humans:
Understanding the role of microRNAs in cancer progression. Cancer
Res. 70:LB–353. 2010.
|
|
20
|
Gozuacik D, Akkoc Y, Ozturk DG and Kocak
M: Autophagy- regulating microRNAs and cancer. Front Oncol.
7:652017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chu R, Mo GQ, Duan Z, Huang M, Chang J, Li
X and Liu P: miRNAs affect the development of hepatocellular
carcinoma via dysregulation of their biogenesis and expression.
Cell Commun Signal. 12:452014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ahmad MK, Waseem M, Serajuddin M, Mahdi
AA, Sankhwar SN and Mishra DP: MicroRNA: A new potential marker for
prostate cancer. Cancer Med. 7:17. 2018.
|
|
23
|
Hironaka-Mitsuhashi A, Matsuzaki J,
Takahashi RU, Yoshida M, Nezu Y, Yamamoto Y, Shiino S, Kinoshita T,
Ushijima T, Hiraoka N, et al: A tissue microRNA signature that
predicts breast cancer recurrence in young women. PLoS One.
12:e01876382017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Baldassari F, Zerbinati C, Galasso M,
Corrà F, Minotti L, Agnoletto C, Previati M, Croce CM and Volinia
S: Screen for MicroRNA and Drug interactions in breast cancer cell
lines points to miR-126 as a modulator of CDK4/6 and PIK3CA
inhibitors. Front Genet. 9:1742018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Frixa T, Sacconi A, Cioce M, Roscilli G,
Ferrara FF, Aurisicchio L, Pulito C, Telera S, Carosi M, Muti P, et
al: MicroRNA-128-3p-mediated depletion of Drosha promotes lung
cancer cell migration. Carcinogenesis. 39:293–304. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Heydari N, Nikbakhsh N, Sadeghi F,
Farnoush N, Khafri S, Bastami M and Parsian H: Overexpression of
serum MicroRNA-140-3p in premenopausal women with newly diagnosed
breast cancer. Gene. 655:25–29. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jiang SB, He XJ, Xia YJ, Hu WJ, Luo JG,
Zhang J and Tao HQ: MicroRNA-145-5p inhibits gastric cancer
invasiveness through targeting N-cadherin and ZEB2 to suppress
epithelial-mesenchymal transition. Oncotargets Ther. 9:2305–2315.
2016.
|
|
28
|
Noh JH, Chang YG, Kim MG, Jung KH, Kim JK,
Bae HJ, Eun JW, Shen Q, Kim SJ, Kwon SH, et al: MiR-145 functions
as a tumor suppressor by directly targeting histone deacetylase 2
in liver cancer. Cancer Lett. 335:455–462. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ding Y, Zhang C, Zhang J, Zhang N, Li T,
Fang J, Zhang Y, Zuo F, Tao Z, Tang S, et al: miR-145 inhibits
proliferation and migration of breast cancer cells by directly or
indirectly regulating TGF-β1 expression. Int J Oncol. 50:1701–1710.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang M, Wang J, Deng J, Li X, Long W and
Chang Y: MiR-145 acts as a metastasis suppressor by targeting
metadherin in lung cancer. Med Oncol. 32:3442015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Azizmohammadi S, Safari A, Azizmohammadi
S, Kaghazian M, Sadrkhanlo M, Yahaghi E, Farshgar R and
Seifoleslami M: Molecular identification of miR-145 and miR-9
expression level as prognostic biomarkers for early-stage cervical
cancer detection. QJM. 110:11–15. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou X, Yue Y, Wang R, Gong B and Duan Z:
MicroRNA-145 inhibits tumorigenesis and invasion of cervical cancer
stem cells. Int J Oncol. 50:853–862. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sathyanarayanan A, Chandrasekaran KS and
Karunagaran D: microRNA-145 downregulates SIP1-expression but
differentially regulates proliferation, migration, invasion and Wnt
signaling in SW480 and SW620 cells. J Cell Biochem. 119:2022–2035.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zheng X, Tang H, Zhao X, Sun Y, Jiang Y
and Liu Y: Long non-coding RNA FTH1P3 facilitates uveal melanoma
cell growth and invasion through miR-224-5p. PLoS One.
12:e01847462017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang R, Zhang T, Yang Z, Jiang C and Seng
J: Long non-coding RNA FTH1P3 activates paclitaxel resistance in
breast cancer through miR-206/ABCB1. J Cell Mol Med. 22:4068–4075.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li C, Lu L, Feng B, Zhang K, Han S, Hou D,
Chen L, Chu X and Wang R: The lincRNA-ROR/miR-145 axis promotes
invasion and metastasis in hepatocellular carcinoma via induction
of epithelial-mesenchymal transition by targeting ZEB2. Sci Rep.
7:46372017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mak IW, Singh S, Turcotte R and Ghert M:
The epigenetic regulation of SOX9 by miR-145 in human
chondrosarcoma. J Cell Biochem. 116:37–44. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kou B, Gao Y, Du C, Shi Q, Xu S, Wang CQ,
Wang X, He D and Guo P: miR-145 inhibits invasion of bladder cancer
cells by targeting PAK1. Urol Oncol. 32:846–854. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xu Q, Liu LZ, Qian X, Chen Q, Jiang Y, Li
D, Lai L and Jiang BH: MiR-145 directly targets p70S6K1 in cancer
cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res.
40:761–774. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Qin J, Wang F, Jiang H, Xu J, Jiang Y and
Wang Z: MicroRNA-145 suppresses cell migration and invasion by
targeting paxillin in human colorectal cancer cells. Int J Clin Exp
Patho. 8:1328–1340. 2015.
|
|
41
|
Zhang X, Dong Y, Ti H, Zhao J, Wang Y, Li
T and Zhang B: Down-regulation of miR-145 and miR-143 might be
associated with DNA methyltransferase 3B overexpression and worse
prognosis in endometrioid carcinomas. Hum Pathol. 44:2571–2580.
2013. View Article : Google Scholar : PubMed/NCBI
|
